Comparison of physiological parameter on vulnerable plaque between PCSK9 inhibitors and statin

Comparison of physiological parameter on vulnerable plaque between PCSK9 inhibitors and statin - Comparison on vulnerable plaque between PCSK9 inhibitors and statin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041269

Enrollment

200

Registered

2020-07-31

Start date

2020-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery diseases

Interventions

The group which was administrated PCSK9 inhibitors for 1 year (PCSK9i group) The group which was administrated statin (statin group)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patiens with coronary artery diseases,a serum LDL-C level more than 70mg/dl, age more than 20, participants have a statin

Exclusion criteria

Exclusion criteria: A pregnancy or inability to provide written informed consent, Participants had already had anti-PCSK9 antibody on admission

Design outcomes

Primary

Measure	Time frame
Comparison of index of microcirculatory resistance between PCSK9 inhibitors and statins at baseline and 1 year	—

Secondary

Measure	Time frame
Comparison of FFR,CFR,maxLCBI4mm between PCSK9 inhibitors and statins at baseline and 1 year	—

Countries

Japan

Contacts

Public ContactHiroyuki Omori

Gifu Heart Center Department of Cardiovascular Medicine

omori@heart-center.or.jp058-277-2277

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026